Jonathan Slonin Biography and Net Worth

Chief Medical Officer of Pacira BioSciences

Dr. Jonathan Slonin joined Pacira in 2020 and most recently served as Chief Clinical Officer, directing the Company’s customer-facing medical operations and iovera device franchise. As Chief Medical Officer, Dr. Slonin will oversee research and development and all customer-facing medical operations in addition to clinical, R&D, and medical strategy. He brings over 15 years of experience to Pacira as a board-certified anesthesiologist who has held numerous clinical and leadership positions with TeamHealth and Envision Healthcare including Regional Medical Director for the Southeast with TeamHealth and Chairman of Anesthesiology for the Cleveland Clinic Martin Health. Dr. Slonin received his Bachelor of Science in Biomedical Engineering and his MD degree from the University of Miami. He completed his anesthesiology residency at University of Miami/Jackson Memorial Hospital where he served as chief resident. Dr. Slonin received his MBA degree from George Washington University.

What is Jonathan Slonin's net worth?: The estimated net worth of Jonathan Slonin is at least $5.54 million as of March 17th, 2026. Dr. Slonin owns 223,640 shares of Pacira BioSciences stock worth more than $5,544,036 as of May 6th. This net worth evaluation does not reflect any other assets that Dr. Slonin may own. Learn More about Jonathan Slonin's net worth.
How do I contact Jonathan Slonin?: The corporate mailing address for Dr. Slonin and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Jonathan Slonin's contact information.
Has Jonathan Slonin been buying or selling shares of Pacira BioSciences?: Jonathan Slonin has not been actively trading shares of Pacira BioSciences during the last quarter. Most recently, Jonathan Slonin sold 3,261 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a transaction totalling $74,416.02. Following the completion of the sale, the insider now directly owns 223,640 shares of the company's stock, valued at $5,103,464.80. Learn More on Jonathan Slonin's trading history.
Who are Pacira BioSciences' active insiders?: Pacira BioSciences' insider roster includes Marcelo Bigal (Director), Shawn Cross (CFO), Mark Froimson (Director), Mark Kronenfeld (Director), Frank Lee (Chief Executive Officer & Director), Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), Lauren Riker (SVP), Jonathan Slonin (Chief Medical Officer), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), Kristen Williams (Chief Administrative Officer & Secretary), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.
Are insiders buying or selling shares of Pacira BioSciences?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 77,087 shares worth more than $1,900,184.49. The most recent insider tranaction occured on April, 23rd when CFO Shawn Cross sold 12,941 shares worth more than $325,595.56. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.
Information on this page was last updated on 4/23/2026.

Jonathan Slonin Insider Trading History at Pacira BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2026	Sell	3,261	$22.82	$74,416.02	223,640
11/17/2025	Sell	3,960	$24.09	$95,396.40	178,367
11/17/2025	Sell	3,960	$24.09	$95,396.40	178,367
1/6/2025	Sell	879	$18.40	$16,173.60	93,444
8/2/2024	Sell	945	$20.05	$18,947.25	94,307
7/2/2024	Sell	2,836	$28.25	$80,117.00	95,557
6/11/2024	Sell	5,012	$28.57	$143,192.84	44,569
7/5/2022	Sell	924	$57.19	$52,843.56	37,387

Jonathan Slonin Buying and Selling Activity at Pacira BioSciences

Pacira BioSciences Company Overview

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Today's Range

Now: $24.79

$24.74

$25.60

50 Day Range

MA: $23.34

$21.28

$25.55

2 Week Range

Now: $24.79

$18.80

$27.64

Volume

761,643 shs

Average Volume

578,908 shs

Market Capitalization

$975.49 million

P/E Ratio

206.60

Dividend Yield

N/A

Beta

0.32